Clinical Report: Acute Administration of TRPTI™ Improves Incretin Hormone Levels
Overview
This study evaluates the acute administration of TRPTI™ and its effects on GLP-1 and GIP hormone levels in healthy adults. The 300 mg dose of TRPTI™ showed increases in hormone levels detectable within 15 minutes.
Background
Oleoylethanolamide (OEA) is a bioactive lipid mediator involved in metabolic regulation and appetite control. This study investigates the effects of TRPTI™, a formulation of OEA, on incretin hormones.
Data Highlights
Parameter
300 mg TRPTI™
Placebo
GLP-1 Concentration Increase
20-25%
Baseline
GIP Concentration Increase
Significant
Baseline
Reduction in Meal Consumption
Yes
No
Key Findings
300 mg TRPTI™ significantly increased GLP-1 and GIP levels compared to placebo.
Elevations in GLP-1 were detectable within 15 minutes post-ingestion.
Both TRPTI™ doses were well-tolerated with safety biomarkers remaining normal.
Significant changes in circulating DPP-4 levels were observed at later time points.
Acute administration of TRPTI™ resulted in a statistically significant reduction in meal consumption.
Clinical Implications
Further research is warranted to explore the role of TRPTI™ in nutritional strategies.
Conclusion
The study indicates that TRPTI™ can enhance incretin hormone levels in healthy adults.
